Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 6, 2006, Pages 1154-1159

  Yan, Meiguan ^a   Sahin, Orhan ^a   Lin, Jun ^a,b   Zhang, Qijing ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Antibiotic resistance; Ciprofloxacin; Efflux; GyrA mutations

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; CME ABC EFFLUX PUMP PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; MEMBRANE PROTEIN; MEROPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; GENE OVEREXPRESSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; REPRESSOR GENE; SEQUENCE ANALYSIS; SPECTROFLUOROMETRY; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CAMPYLOBACTER; CIPROFLOXACIN; CYTOPLASM; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POINT MUTATION; SELECTION (GENETICS); SEQUENCE ANALYSIS, DNA; SPECTROMETRY, FLUORESCENCE;

EID: 33845353844     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl412     Document Type: Article

References (40)

1. Samuel MC, Vugia DJ, Shallow S et al. Epidemiology of sporadic Campylobacter infection in the United States and declining trend in incidence, FoodNet 1996-1999. Clin Infect Dis 2004; 38 Suppl 3: 165-74.
2. Nylen G, Dunstan F, Palmer SR et al. The seasonal distribution of Campylobacter infection in nine European countries and New Zealand. Epidemiol Infect 2002; 128: 383-90.
3. Friedman CR, Nelmann J, Waegener HG et al. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, eds. Campylobacter, 2nd edn. Washington, DC: American Society for Microbiology, 2000; 121-39.
4. Mishu B, Blaser MJ. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barre syndrome. Clin Infect Dis 1993; 17: 104-8.
5. Koga M, Gilbert M, Takahashi M et al. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Infect Dis 2006; 193: 547-55.
6. Oldfield EC III, Wallace MR. The role of antibiotics in the treatment of infectious diarrhea. Gastroenterol Clin North Am 2001; 30: 817-36.
7. Aarestrup FM. Occurrence, selection and spread of resistance to antimicrobial agents used for growth promotion for food animals in Denmark. APMIS 2000; 101 Suppl: 1-48.
8. Jain D, Sinha S, Prasad KN et al. Campylobacter species and drug resistance in a north Indian rural community. Trans R Soc Trop Med Hyg 2005; 99: 207-14.
9. Hoge CW, Gambel JM, Srijan A et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341-5.
10. Bywater RJ. Veterinary use of antimicrobials and emergence of resistance in zoonotic and sentinel bacteria in the EU. J Vet Med B 2004; 51: 361-3.
11. Takkinen J, Ammon A, Robstad O et al. European survey on Campylobacter surveillance and diagnosis 2001. Euro Surveill 2003; 8: 207-13.
12. Angulo FJ, Nargund VN, Chiller TC. Evidence of an association between use of anti-microbial agents in food animals and anti-microbial resistance among bacteria isolated from humans and the human health consequences of such resistance. J Vet Med B 2004; 51: 374-9.
13. Hamer DH, Gill CJ. From the farm to the kitchen table: The negative impact of antimicrobial use in animals on humans. Nutr Rev 2002; 60: 261-4.
14. Luo N, Pereira S, Sahin O et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Nalt. Acad Sci USA 2005; 102: 541-6.
15. Engberg J, Neimann J, Nielsen EM et al. Quinolone-resistant Campylobacter infections: Risk factors and clinical consequences. Emerg Infect Dis 2004; 10: 1056-63.
16. Helms M, Simonsen J, Olsen KE et al. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: A registry-based cohort study. J Infect Dis 2005; 191: 1050-5.
17. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7: 337-41.
18. Drlica K, Malik M. Fluoroquinolones: Action and resistance. Curr Top Mad Chem 2003; 3: 249-82.
19. Bachoual R, Ouabdesselam S, Mory F et al. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Microb Drug Resist 2001; 7: 257-61.
20. Wang Y, Huang WM, Taylor DE. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob Agents Chemother 1993; 37: 457-63.
21. Taylor DE, Chau AS. Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates. Antimicrob Agents Chemother 1997; 41: 665-71.
22. Ruiz J, Goni P, Marco F et al. Increased resistance to quinolones in Campylobacter jejuni: A genetic analysis of gyrA gene mutations in quinolone-resistant clinical isolates. Microbiol Immunol 1998; 42: 223-6.
23. Luo N, Sahin O, Lin J et al. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. Antimicrob Agents Chemother 2003; 47: 390-4.
24. Zhang Q, Lin J, Pereira S. Fluoroquinolone-resistant Campylobacter in animal reservoirs: Dynamics of development, resistance mechanisms and ecological fitness. Anim Health Res Rev 2003; 4: 63-71.
25. Charvalos E, Tselentis Y, Hamzehpour MM et al. Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. Antimicrob Agents Chemother 1995; 39: 2019-22.
26. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother 2002; 46:2124-31.
27. Lin J, Sahin O, Michel LO et al. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni. Infect Immun 2003; 71: 4250-9.
28. Pumbwe L, Piddock LJ. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol Lett 2002; 206: 185-9.
29. Lin J, Akiba M, Sahin O et al. CmeR functions as a transcriptional repressor for the multidrug efflux pump CmeABC in Campylobacter jejuni. Antimicrob Agents Chemother 2005; 49: 1067-75.
30. Gootz TD, Martin BA. Characterization of high-level quinolone resistance in Campylobacter jejuni. Antimicrob Agents Chemother 1991; 35: 840-5.
31. McDermott PF, Bodeis SM, English LL et al. Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. J. Infect Dis 2002; 185: 837-40.
32. Jacobs-Reitsma WF, Kan CA, Bolder NM. The induction of quinolone resistance in Campylobacter bacteria in broilers by quinolone treatment. Lett Appl Microbiol 1994; 19: 228-31.
33. Wretlind B, Stromberg A, Ostlund L et al. Rapid emergence of quinolone resistance in Campylobacter jejuni in patients treated with norfloxacin. Scand J Infect Dis 1992; 24: 685-6.
34. Lomovskaya O, Lee A, Hoshino K et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1340-6.
35. Jumbe NL, Louie A, Miller MH et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 310-7.
36. Akiba M, Lin J, Barton YW et al. Interaction of CmeABC and CmeDEF in conferring antimicrobial resistance and maintaining cell viability in Campylobacter jejuni. J Antimicrob Chemother 2006; 57: 52-60.
37. Lin J, Cagliero C, Guo B et al. Bile salts modulate expression of the CmeABC multidrug efflux pump in Campylobacter jejuni. J Bacteriol 2005; 187:7417-24.
38. Payot S, Avrain L, Magras C et al. Relative contribution of target gene mutation and efflux to fluoroquinolone and erythromycin resistance, in French poultry and pig isolates of Campylobacter coli. Int J Antimicrob Agents 2004; 23: 468-72.
39. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fiteenth informational supplement M100-515. CLSI, Wayne, PA, USA, 2005.
40. Chuma T, Maeda T, Niwa H et al. Acquisition of quinolone resistance and point mutation of the gyrA gene in Campylobacter jejuni isolated from broilers and in vitro-induced resistant strains. J Vet Med Sci 2004; 66: 155-60.